In their review of the function of cytochrome P450 pharmacogenomics in patients with persistent non-cancer pain, Tverdohleb et al. placed special emphasis on the genotyping of CYP2D6 expression and how its high polymorphism affects how opioid drugs are metabolized [90]. Here, CYP2D6 is linked to cancer.